Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

REPL vs LCTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REPL Captures Overall Composite Edge (38.9 SELL vs 58.9 HOLD), While LCTX Leads 3–2 on Growth & Valuation Pillars

REPL Overall Winner 6-Pillar Tally: REPL 2 – 3 LCTX (1 Tie) Matrix Metrics: REPL 4 – 6 LCTX

As of Nov 19, 2026, Replimune Group, Inc. (REPL) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (38.9/100 SELL vs. 58.9/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. REPL trades at $19.23 (N/M Forward P/E, 0.0% operating margin) versus LCTX at $0.82 (30.7x Forward P/E, -280.3% operating margin).

  • Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. REPL 38.9/100 SELL), REPL captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY).
  • Technical & Structure Timing Caution: REPL trades in a Markup technical trend (BREAKOUT options phase, RSI 55.1); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About REPL vs LCTX
REPL NASDAQ Head-to-Head Winner
Replimune Group, Inc.
Biological Products, (No Disgnostic Substances)
$19.23
-2.93% 1D
Market Cap $1.9B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.09β · 107% Vol
Unified Composite Score
38.9 / 100 SELL
Tech 28.0 Fund 48.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (11.9% over 20 days), RSI 55
RSI-14: 55.1 · SMA20: $19.09 · SMA50: $15.22
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.3%), weak momentum, RSI 37
RSI-14: 37.1 · SMA20: $0.98 · SMA50: $0.98

6-Pillar Scorecard Institutional Category Breakdown (REPL 2 – 3 LCTX)

Columns: Metric · REPL · LCTX
1. Valuation Multiples LCTX
Forward P/E N/M 30.7x
Trailing P/E N/M 30.7x
PEG Ratio N/M 10.64x
EV / Revenue N/M 16.3x
2. Growth & Scale REPL
Revenue Growth (YoY) +0.0% -61.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $11M
Market Cap $1.9B $212.1M
3. Profitability & Quality LCTX
Gross Margin N/A -95.0%
Operating Margin 0.0% -280.3%
Net Profit Margin 0.0% 16.2%
Return on Equity (ROE) -115.8% 4.3%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$246M -$24M
Cash Flow Margin N/A N/A
Net Cash / Leverage $181M Net Cash $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning REPL
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 90.1% (9th %ile) 896.2% (100th %ile)
Put/Call OI Skew 0.10x (Call-Skewed) 1.10x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: REPL (4) vs LCTX (6)
Institutional Metric REPL LCTX Criterion Row Edge
Market Capitalization
Scale
$1.9B $212.1M Larger Scale REPL
Trailing P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY)
Growth
+0.0% -61.0% Higher Growth REPL
Operating Margin (TTM)
Profitability
0.0% -280.3% Higher Margin REPL
Net Profit Margin
Profitability
0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
-115.8% 4.3% Higher ROE LCTX
52-Week Range Position
Momentum
80% ($2–$24) 4% ($1–$2) Stronger Trend REPL
Beta / 30D Volatility
Risk Regime
2.09β · 107% Vol 1.36β · 79% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
38.9 / 100 (SELL) 58.9 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 10.64x PEG · 16.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$246M ($181M Net Cash) -$24M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REPL +77.9 pp
REPL: +64.08% · LCTX: -13.82%
3M Horizon REPL +54.27 pp
REPL: +30.2% · LCTX: -24.07%
6M Horizon REPL +309.1 pp
REPL: +272.67% · LCTX: -36.43%
1Y Horizon REPL +173.69 pp
REPL: +120.02% · LCTX: -53.67%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REPL vs LCTX. Trailing 12-month operating profitability (REPL 0.0% vs LCTX -280.3%) and valuation multiples (REPL N/M vs LCTX 30.7x Forward P/E) are benchmarked directly in Pillar 4 below.

REPL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-115.8% · N/M
LCTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin-95.0%
Op. Margin-280.3%
ROE / Fwd P/E4.3% · 30.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
REPL BREAKOUT
101d in phase · OBV NEUTRAL
Current IV 90.1%
IV Percentile 9th %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact REPL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $21.41 · IV 88.6%

REPL Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($2,141)

Compare $2,141 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 88.6% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $21 / $25 Bull Call Spread

Buy 1x $21C · Sell 1x $25C · 32d

Net Entry $154 Debit
T+5d @ +5% Move +$26 (+17%)
Max Risk / Buffer $154 Capped
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $19 / $18 Bull Put Spread

Sell 4x $19P · Buy 4x $18P · 60d

Net Entry $232 Credit
Max Credit / Yield +$232 (+138.1% RoM)
Max Risk / Buffer -14.0% Cushion ($168 Mgn)
5d Edge & Liquidity 70% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
REPL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ REPL vs LCTX Key Questions & Quantitative Answers

As of Nov 19, 2026, Replimune Group, Inc. (REPL) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (38.9/100 SELL vs. 58.9/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. REPL trades at $19.23 (N/M Forward P/E, 0.0% operating margin) versus LCTX at $0.82 (30.7x Forward P/E, -280.3% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. REPL 38.9/100 SELL), REPL captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY). Technical & Structure Timing Caution: REPL trades in a Markup technical trend (BREAKOUT options phase, RSI 55.1); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

REPL leads the Growth & Scale pillar: REPL posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). On trailing 12-month operating scale, REPL generates N/A in USD-normalized revenue versus $11M for LCTX. In operating R&D and SG&A reinvestment, REPL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.

LCTX screens cheaper on headline valuation multiples. REPL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REPL (-115.8% ROE) versus LCTX (4.3% ROE) capital efficiency.

In options market volatility and institutional positioning, REPL carries 90.1% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (2.09β · 107% Vol realized risk). By comparison, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.